The Sonire Therapeutics ultrasound system is currently being studied for the treatment of patients with unresectable pancreatic cancer refractory or intolerant to first-line chemotherapy.
The Food and Drug Administration (FDA) has issued a breakthrough device designation to Sonire Therapeutics for the use of its high-intensity focused ultrasound (HIFU) system (Suizenji) to treat pancreatic cancer, a disease that may claim the lives of 51,750 people in the United States in 2024, according to estimates from the American Cancer Society.1,2
Through the use of cavitation ultrasound, Sonire Therapeutics said the Suizenji HIFU system facilitates the delivery of thermal therapy with lower acoustic energy in addition to providing image clarity for targeted treatment.3
“These are key features to achieve both safety and treatment throughput in our system,” noted Tohru Satoh, the chief executive officer of Sonire Therapeutics, in a 2023 interview.3
Researchers are currently comparing adjunctive use of the emerging HIFU system with second-line chemotherapy versus chemotherapy alone in a phase 2 trial for the treatment of patients with unresectable pancreatic cancer refractory or intolerant to initial chemotherapy, according to Sonire Therapeutics.
References
1. Sonire Therapeutics. Sonire’s HIFU therapy system designated as breakthrough device by FDA. PR Newswire. Available at: https://www.prnewswire.com/news-releases/sonires-hifu-therapy-system-designated-as-breakthrough-device-by-fda-302277187.html . Published October 16, 2024. Accessed October 16, 2024.
2. American Cancer Society. Key statistics for pancreatic cancer. Available at: https://www.cancer.org/cancer/types/pancreatic-cancer/about/key-statistics.html#:~:text=The%20average%20lifetime%20risk%20of,Cancer%20Survival%20Rates%20by%20Stage. . Accessed October 16, 2024.
3. Focused Ultrasound Foundation. Company profile: Sonfire Therapeutics. Available at: https://www.fusfoundation.org/posts/company-profile-sonire-therapeutics/#:~:text=We%20spoke%20with%20the%20SONIRE's,what%20makes%20their%20device%20unique. . Published February 22, 2023. Accessed October 16, 2024.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can Intestinal Ultrasound Provide an Alternative for Evaluating Creeping Fat with Crohn’s Disease?
September 25th 2024Intestinal ultrasound demonstrated an 88.2 percent agreement with computed tomography enterography in characterizing creeping fat in patients with Crohn’s disease, according to new research.
FDA Clears Enhanced 3D Ultrasound Platform for Thyroid Imaging
September 23rd 2024The Piur tUS Infinity system reportedly reduces operator dependency with ultrasound through upgrading of two-dimensional ultrasound devices and access to 3D multiplanar image reconstructions of thyroid conditions.